Vmbook Online ordering

Therabiogen Inc

Iflolow, thank you for reaching out to me. I am glad to provide you with general information about the public company Therabiogen Inc.

Therabiogen Inc. is a clinical-stage biopharmaceutical company focused on the design and development of innovative (T cell) immunotherapies to treat cancer. The company was founded in 2014 and is headquartered in South San Francisco, California.

Therabiogen's lead product candidates are T cell therapies that have the potential to treat hematological malignancies and solid tumors. The company is currently conducting clinical trials for its lead product candidates, including a Phase 1 trial for its T cell therapy targeting CD19-positive hematological malignancies and a Phase 1/2 trial for its T cell therapy targeting solid tumors.

Therabiogen's stock is listed on the NASDAQ stock exchange under the ticker symbol Tbio. As of February 2023, the company has a market capitalization of approximately $1.2 billion.

It is important to note that investing in the stock market always carries risks, and it is essential to conduct thorough research and seek advice from a financial advisor before making any investment decisions.

I hope this information is helpful to you. If you have any further questions, please let me know.